Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-8245 · 1 trial · 1 indication
The 24-hour WMG is derived from multiple glucose values collected during both fasting and post-meal periods. A "weighted" rather than a "simple" mean is used to avoid overrepresentation of post-meal glucose values. Blood samples for glucose were collected immediately prior to, and after each meal, and overnight and fasting one hour pre-dose.
An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. A serious AE is any untoward medical occurrence that results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.
An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
| Arm | Type | Description |
|---|---|---|
| MK-8245 50 mg | EXPERIMENTAL | MK-8245, 50 mg, twice daily for 28 days |
| Placebo | PLACEBO_COMPARATOR | Placebo to MK-8245, 50 mg, twice daily |
| Name | Type | Description |
|---|---|---|
| MK-8245 | DRUG | MK-8245 50 mg twice daily for 28 days |
| Comparator: placebo | DRUG | matching placebo to MK-8245 twice daily for 28 days |
Inclusion Criteria: * Subject has a diagnosis of type 2 diabetes and is being treated with diet and exercise alone, a single oral anti-hyperglycemic agent or a combination of two oral anti-hyperglycemic agents * Subject is willing to follow a weight-maintaining diet and exercise program during the ...
MK-8245 is an investigational small molecule being developed for the treatment of Type 2 Diabetes and Type 2 Diabetes Mellitus. It is in Phase 1 clinical development and is not yet approved by regulatory authorities.
MK-8245 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
MK-8245 is in Phase 1 clinical development. It is an investigational drug and has not received regulatory approval. Clinical trials are ongoing to assess its safety, tolerability, and pharmacological effects in patients with Type 2 Diabetes.
MK-8245 has been studied in two completed Phase 1 clinical trials: NCT00790556 and NCT00972322. These trials evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of the drug in participants with Type 2 Diabetes.
MK-8245 and MK8245 refer to the same investigational drug. The naming convention may vary in different contexts, but both names denote the same compound being developed by Merck & Company, Inc. for Type 2 Diabetes.